Frankfurt - Delayed Quote EUR

Ascentage Pharma Group International (36X.F)

5.05

+0.29

+(6.09%)

As of 9:59:02 AM GMT+2. Market Open.

Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said two of its proprietary drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The added drugs are lisaftoclax and olverembatinib; the former used to diagnose and treat lymphoid malignancies, while the latter treats leukemias in children and adolescent as well […]

Exec Edge yesterday

AAPG

ASPHF
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company’s investigational novel or

GlobeNewswire yesterday

AAPG

ASPHF
Stocks To Watch In Gloomy Market — Including This Breakout IPO

In troubled market, insurance stocks, gold, energy, education and this hot Chinese biotech IPO lead this brigade of stocks to watch.

Investor's Business Daily 20 days ago

AEM

AAPG

ASPHF
Asian Growth Stocks With Strong Insider Confidence

In the current climate of heightened uncertainty and mixed economic signals, Asian markets have shown resilience, with some sectors experiencing growth despite global challenges. In this environment, companies with strong insider ownership can signal confidence in their long-term prospects, making them attractive to investors seeking stability and potential growth.

Simply Wall St. 26 days ago

DPCDF

AAPG

ASPHF
Exploring XD And Two Other High Growth Tech Stocks In Asia

As global markets navigate a landscape of economic uncertainty and mixed signals, with tech stocks in the U.S. recently lagging behind broader indices, investors are increasingly turning their attention to Asia's high-growth tech sector for potential opportunities. In this environment, identifying strong stocks often involves looking at companies that demonstrate resilience and adaptability amid changing economic forecasts and geopolitical risks, as these qualities can be crucial for...

Simply Wall St. 26 days ago

AAPG

ASPHF

XDNCF
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Revenue in 2024 increased 342% year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong sales growth of olverembatinib Sales of olverembatinib in China in 2024 increased 52% year-over-year to US$33.0 million Completion of U.S. initial public offering on Nasdaq in January 2025, resulting in US$132.5 million in net proceedsLisaftoclax accepted for New Drug Application (NDA) review with Priority Review designation in ChinaTen registrational t

GlobeNewswire 26 days ago

AAPG

ASPHF
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

ROCKVILLE, Md. and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that five abstracts highlighting the latest preclinical results from its pipeline programs have been selected for presentations at the 2025 American Association of Cancer Research Annual Me

GlobeNewswire 28 days ago

AAPG

ASPHF
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that it will release full year 2024 financial results, and provide an update on recent developments on March 27, 2025 at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT).

GlobeNewswire last month

AAPG

ASPHF
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib, is first-line treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination […]

Exec Edge last month

AAPG

ASPHF
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA),

GlobeNewswire last month

AAPG

ASPHF
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (“ADSs”) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma.

GlobeNewswire 2 months ago

AAPG

ASPHF
Ascentage Pharma Announces Closing of U.S. Initial Public Offering

ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expen

GlobeNewswire 2 months ago

AAPG

AAPGV

ASPHF
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expen

GlobeNewswire 2 months ago

ASPHF
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that its Chairman and CEO, Dr. Dajun Yang, has accepted an invitation to present on the company's progress and prospects under its patient-centric global innovation strategy, at 1:15 PM, January 16, 2025, Pacific Time (5:15 AM, January 17, 2025, Beijing Time) at the 43rd Annual J.P. Morga

PR Newswire 3 months ago

ASPHF
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in patients with relapsed/refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis, in an Oral Report at the 66th American Society of Hematology (ASH)

PR Newswire 4 months ago

ASPHF
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the follow-up safety and efficacy data of the company's investigational Bcl-2 selective inhibitor, lisaftoclax (APG-2575), in combination with azacitidine (AZA) for the treatment of patients with myelodysplastic syndrome (MDS), in a Poster Presentation at the 66th Ame

PR Newswire 4 months ago

ASPHF
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data from a global study of its novel drug candidate, olverembatinib (HQP1351), in patients with heavily pretreated chronic myeloid leukemia (CML), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking pla

PR Newswire 4 months ago

ASPHF
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking

PR Newswire 4 months ago

ASPHF
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof. Weiming Li, of Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has presented the latest clinical data of its novel drug candidate, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leuk

PR Newswire 4 months ago

ASPHF
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the safety and efficacy data of the company's novel drug candidate, olverembatinib (HQP1351), in combination the company's investigational novel Bcl-2 inhibitor, lisaftoclax (APG-2575), in children and adolescents with relapsed/refractory Philadelphia chromosome–posit

PR Newswire 4 months ago

ASPHF

Performance Overview

Return	36X.F	HANG SENG INDEX (^HSI)
YTD	-9.82%	+10.03%
1-Year	+164.40%	+31.16%
3-Year	+225.81%	+6.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ascentage Pharma Group International (36X.F)

Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

Stocks To Watch In Gloomy Market — Including This Breakout IPO

Asian Growth Stocks With Strong Insider Confidence

Exploring XD And Two Other High Growth Tech Stocks In Asia

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Performance Overview